CF PHARMTECH (02652) announced that the Investigational New Drug (IND) application for its self-developed candidate drug ICF004, an inhaled dry powder formulation, has been accepted by China's National Medical Products Administration (NMPA). ICF004 is intended for the treatment of progressive fibrosing interstitial lung diseases, including life-threatening conditions such as idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The drug utilizes an inhaled dry powder delivery method designed to administer medication directly to the affected areas of the lungs, thereby increasing local exposure while minimizing systemic exposure, aiming for a more favorable balance between efficacy and safety. In completed preclinical studies, ICF004 demonstrated differentiated distribution characteristics, showing high exposure in lung tissue and low systemic exposure. These findings support a development strategy focused on enhancing delivery efficiency to the target organ through local administration while reducing systemic burden. Additionally, observed trends of anti-fibrotic activity in relevant preclinical models provide preliminary supportive evidence for further clinical development; however, whether these results will translate into clinical efficacy and safety benefits in humans remains to be verified in future clinical trials. The acceptance of the application marks a significant milestone in the company's innovative drug development process and further demonstrates the transformative potential of its complex respiratory formulation and precision delivery platform. The company believes that the progress of the ICF004 project showcases its ability to integrate complex formulations, delivery systems, and device engineering to address unmet clinical needs, laying a methodological foundation for future respiratory innovation projects and highlighting its long-term potential in delivery-enabled innovative drug development beyond its core complex formulation business. The group will maintain active communication with the NMPA and advance subsequent clinical activities in accordance with regulatory requirements.